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Drug targeting systems are nanometer-sized carrier materials designed for improving the biodistribution of systemically applied
(chemo-) therapeutics. Reasoning that (I) the temporal and spatial interaction between systemically applied chemotherapy and
clinically relevant fractionated radiotherapy is suboptimal, and that (II) drug targeting systems are able to improve the temporal and
spatial parameters of this interaction, we have here set out to evaluate the potential of ‘carrier-based radiochemotherapy’.
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were used as a model drug targeting system, doxorubicin and gemcitabine
as model drugs, and the syngeneic and radio- and chemoresistant Dunning AT1 rat prostate carcinoma as a model tumour model.
Using magnetic resonance imaging and g-scintigraphy, the polymeric drug carriers were first shown to circulate for prolonged periods
of time, to localise to tumours both effectively and selectively, and to improve the tumour-directed delivery of low molecular weight
agents. Subsequently, they were then shown to interact synergistically with radiotherapy, with radiotherapy increasing the tumour
accumulation of the copolymers, and with the copolymers increasing the therapeutic index of radiochemotherapy (both for
doxorubicin and for gemcitabine). Based on these findings, and on the fact that its principles are likely broadly applicable, we propose
carrier-based radiochemotherapy as a novel concept for treating advanced solid malignancies.
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The combination of radiotherapy and chemotherapy has been
evaluated extensively in the past few decades (Vokes and
Weichselbaum, 1990; Seiwert et al, 2007). Besides significantly
increasing the efficacy of radiotherapy, however, the simultaneous
application of chemotherapy also substantially increases its
toxicity (Maduro et al, 2003; Rowell and O’rourke, 2004). As
external beam radiotherapy can nowadays be delivered with
extremely high levels of spatial specificity (Fuks et al, 1991; Bernier
et al, 2004), this is likely mostly due to the low degree of spatial
specificity that chemotherapeutic agents generally present upon
intravenous (i.v.) administration. Based on this notion, and on the
fact that drug targeting systems are known to be able to improve
both the temporal (circulation time, tumour residence time) and
the spatial (tumour accumulation, tumour-to-organ ratio) para-
meters of drug therapy (Moses et al, 2003; Torchilin, 2005;
Duncan, 2006; Lammers et al, 2008), we reasoned that the
implementation of a drug targeting system might be able to
increase the therapeutic index of radiochemotherapy. The
rationale for this novel combination regimen, which we have
termed ‘carrier-based radiochemotherapy’, relies on the notion
that on the one hand, radiotherapy improves drug targeting (i.e.
the tumour accumulation of drug targeting systems), and that on
the other hand, drug targeting improves radiochemotherapy (i.e.,
the temporal and spatial interaction between daily radiotherapy
and weekly chemotherapy; see Figure 1).
Concerning the former aspect of carrier-based radiochemo-
therapy, several different mechanisms can be envisioned by which
radiotherapy increases the tumour accumulation of drug targeting
systems (Figure 1B). Besides reflecting, for instance, on the
integrity and function of the tumour vasculature (V), and on the
expression of certain cellular receptors (R), it is also known to
affect several cell membrane-related (C), nuclear (N), mitochon-
drial (M) and signalling (S) processes. By eliciting such effects,
radiotherapy has been shown to induce (I) an increase in the
production of vascular endothelial growth factor (VEGF)
(Park et al, 2001) and fibroblast growth factor (FGF) (Lee et al,
1995), (II) an increase in apoptosis and endothelial cell apoptosis
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s(Garcia-Barros et al, 2003), (III) a decrease in tumour cell density
(Peschke et al, 1999), and (IV) a reduction in interstitial fluid
pressure (Znati et al, 1996). By means of the former phenomenon,
radiotherapy is considered to be able to increase the permeability
of the vasculature towards long-circulating nanomedicines
(Samaniego et al, 1998; Feng et al, 1999), and by means of the
latter three, it likely improves their penetration and their intra-
tumoral distribution (Jain, 1994; Netti et al, 1995; Au et al, 2001).
The rationale for the latter aspect of carrier-based radio-
chemotherapy, that is, for the assumption that drug targeting
systems are able to improve the interaction between radiotherapy
and chemotherapy, is depicted schematically in Figure 1C. Drug
targeting systems are generally designed to be stable in circulation,
and to release the conjugated or entrapped active agent only at the
target site (Torchilin, 2005; Duncan, 2006; Lammers et al, 2008). As
a result, as compared to an i.v. applied free drug, the peak plasma
concentration of a tumour-targeted agent tends to be reduced, and
the degree of systemic toxicity can often be attenuated (Figure 1C;
upper two panels). For doxorubicin, for instance, both polymeric
(Yeung et al, 1991; Duncan, 2006) and liposomal (Ewer et al, 2004;
Torchilin, 2005) drug targeting systems have been shown to be able
to reduce the incidence of cardiomyopathy. At the same time, by
increasing the concentration of the active agent at the target site,
drug targeting systems also tend to be able to improve the efficacy
of the drug (Moses et al, 2003; Torchilin, 2005; Duncan, 2006;
Lammers et al, 2008). As a matter of fact, as depicted schematically
in the lower two panels in Figure 1C, the implementation of a drug
targeting system generally not only increases the concentration of
the active agent at the target site, but it also improves its
availability over time (i.e., its area under the curve, as a result of
the enhanced permeability and retention (EPR) effect (Maeda et al,
2000)). When combining a clinically relevant regimen of (weekly)
chemotherapy with a clinically relevant regimen of (daily) radio-
therapy, it can therefore be expected that a drug delivered to the
tumour by means of a drug targeting system interacts more
effectively with radiotherapy than does a free, untargeted drug
(Figure 1D). As will be outlined below, this was indeed found to be
the case, and both for doxorubicin and for gemcitabine, it could be
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Figure 1 Rationale for carrier-based radiochemotherapy. (A) Carrier-based radiochemotherapy is based on the notion that drug targeting and
radiotherapy interact synergistically, with on the one hand, radiotherapy improving the tumour accumulation of drug targeting systems, and with on the other
hand, drug targeting systems improving the therapeutic index of radiochemotherapy. (B) Potential physiological mechanisms by which radiotherapy increases
the tumor accumulation of drug targeting systems. See text for details. (C) Schematic representation of the blood and tumour concentrations of an
intravenously (i.v.) applied free drug (upper and lower left panels), and of a drug delivered to the tumour by means of an i.v. applied drug targeting system
(upper and lower right panels). The arrows indicate the administration of fractionated radiotherapy, which is routinely applied on every weekday for several
consecutive weeks. TT: toxicity threshold, AT: activity threshold. See text for details. (D) Schematic representation of the in vivo interaction between
radiotherapy and chemotherapy upon standard and upon carrier-based radiochemotherapy, exemplifying that in case of the latter, the temporal and spatial
interaction between the two treatment modalities is improved.
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sdemonstrated that drug targeting systems increase the efficacy of
radiochemotherapy without increasing its toxicity.
MATERIALS AND METHODS
Synthesis and characterisation of the copolymers
The tyrosinamide (TyrNH2)-, gadolinium (Gd)- and doxorubicin-
containing N-(2-hydroxypropyl)methacrylamide (HPMA) copoly-
mers were synthesised as described previously (Lammers et al,
2005; Kiessling et al, 2006). Details on the synthesis of these
copolymers, as well as on the preparation of the two newly
generated gemcitabine-containing copolymers are provided as
Supplementary Information online. The weight- and number-
average molecular weights (Mw and Mn) and the polydispersity
(Mw/Mn) of the copolymers were determined by size exclusion
chromatography, and the amounts of doxorubicin and gemcita-
bine incorporated by means of spectrophotometry. The (weight-)
average molecular weights of the two tyrosinamide-containing
copolymers (i.e., poly(HPMA-co-MA-TyrNH2)) were 30.5 and
64.5kDa, their polydispersities were 1.3 and 1.2, and the amounts
of tyrosinamide, included to allow for radiolabeling, were 0.8 and
1.1mol%. The average molecular weight of the gadolinium-labelled
copolymer (i.e., poly(HPMA-co-MA-AH-Asp-[(Asp-(OH)2]2)-
gadolinium) was 24.8kDa, its polydispersity was 1.9 and the
amount of gadolinium was 5.2wt% (as determined by inductively
coupled plasma mass spectrometry). The average molecular
weights of poly(HPMA)-GFLG-Dox (i.e., PK1) and human
immunoglobulin G-modified poly(HPMA)-GFLG-Dox (i.e., IgG-
PK1) were 27.9 and 900kDa, their polydispersities were 1.5 and 4.0,
and relative amounts of doxorubicin were 6.5 and 4.8wt%,
respectively. The average molecular weights of A-Gem (i.e., poly
(HPMA)-AH-Gem; uncleavable) and of B-Gem (i.e., poly(HPMA)-
GFLG-Gem; cleavable) were 20.2 and 24.0kDa, their polydisper-
sities were 1.5 and 1.6, and their drug contents were 6.8 and
10.9wt%, respectively.
Drug release and in vitro efficacy of the Gem-containing
copolymers
The release of Gem from A-Gem and from B-Gem was investigated
at pH¼7.4, at pH¼6.0, and at pH¼6.0 in the presence of the
lysosomal cysteine protease cathepsin B. The temperature was set
to resemble physiological conditions (i.e., 371C). The concentra-
tions of the two polymeric prodrugs were 2.3 10
 3moll
 1 Gem
equivalent. The concentration of cathepsin B was 1.9 10
 7moll
 1,
and its activity was standardised using the substrate a-N-benzoyl-
DL-arginine b-naphthylamide. Drug release was quantified spectro-
photometrically at 310nm. The cytotoxicity of free and HPMA
copolymer-bound gemcitabine was determined by seeding Dunning
AT1 rat prostate carcinoma cells and A2780 human ovarian
carcinoma cells into six-well plates, and by incubating them with
increasing concentrations of the free drug, the two polymeric agents,
and a drug-free control copolymer. Eight to ten days later, the cells
were fixed and stained with crystal violet, and the number of
surviving colonies was counted.
Biodistributional analyses
The tumour and organ accumulation of the copolymers were
evaluated by means of magnetic resonance imaging (MRI) and
g-scintigraphy. The former was performed using a clinical 1.5T
whole-body MRI system (Siemens Symphony) and a custom-made
radio frequency (RF) coil (Kiessling et al, 2006). To optimise the
signal-to-noise ratio, manual tuning and matching of the RF coil’s
circuitry was performed before each individual measurement.
Additional details on the MRI-based biodistributional analyses are
presented as Supplementary Information. For the scintigraphic
analyses, two differently sized poly(HPMA-co-MA-TyrNH2)
conjugates were radiolabeled with iodine-131 (by means of
the Iodogen method). Labelling efficacies were always 495%
(Lammers et al, 2006). Five hundred microliters of a saline
solution containing 0.1mM of the labelled copolymers (B300mCi)
were subsequently injected i.v. into male Copenhagen rats. At
several different time points p.i., blood samples were collected for
kinetic analyses, and the biodistribution of the copolymers was
visualised by means of a Searle-Siemens scintillation camera. At 24
and 168h, animals were killed, and tumours and organs were
harvested for quantification. The residual amounts of radioactivity
were determined using a gamma counter, they were corrected for
radioactive decay and they were expressed as percent of the
injected dose per gram tissue.
Therapeutic analyses
All experiments involving animals were approved by an external
committee for animal welfare and were performed according to
the guidelines for laboratory animals established by the German
government. Experiments were performed on 6–12 month old
male Copenhagen rats, using the syngeneic and radio- and
chemoresistant Dunning AT1 prostate carcinoma model. Fresh
pieces (B10mm
3) of an AT1 donor tumour were transplanted
subcutaneously into both hind limbs of the animals. Prior to
treatment, tumours were grown for 6–8 days, until they reached an
average diameter of 6mm. Free doxorubicin was administered at
its maximum tolerated dose (MTD), that is, at three doses of
2.5mgkg
 1 (days 1, 8 and 15). PK1 was applied at three
(doxorubicin-equivalent) doses of 5mgkg
 1, and IgG-PK1 at both
the 2.5 and 5mgkg
 1 regimen. Local external beam radiotherapy
was delivered by means of the Siemens Gammatron S (cobalt-60
g-irradiation; dose rate B0.5Gymin
 1) and it was applied at a
regimen comparable to that routinely used in clinics: 2Gy was
given on every weekday for four consecutive weeks, i.e., for a total
of 20 doses of 2Gy (days 1–5, 8–12, 15–19, and 22–26).
gemcitabine and the gemcitabine-containing copolymers were
administered four times at a dose of 3mgkg
 1 (days 1, 8, 15, and
22). In this case, radiotherapy was delivered three times weekly for
4 weeks at a dose of 3Gy, that is, for a total of 12 doses of 3Gy
(days  1, 1, 3, 6, 8, 10, 13, 15, 17, 20, 22, and 24). Tumour volumes
were calculated using the formula V¼(a (b b))/2, and they
were expressed relative to the volume determined on the first day
of therapy. The toxicity of the combination regimens was assessed
by determining the body weight loss of the animals and by
analysing the number of white blood cells, red blood cells, and
platelets (Bayer Advia 120 hematology analyzer).
Statistical analysis
Values are expressed as average±s.d. or as average±s.e.m. In the
biodistributional analyses, the two-tailed t-test (for standard
comparisons) or the paired t-test (for the left vs right comparisons)
was used. In the therapeutic analyses, the Mann–Whitney U-test
(i.e., Wilcoxon rank-sum) was used. Bonferroni–Holm post hoc
analysis was used to correct for multiple comparisons. In all cases,
Po0.05 was considered to represent statistical significance.
RESULTS
Biodistributional analysis of HPMA copolymers
To assess the validity and the therapeutic potential of carrier-based
radiochemotherapy, HPMA copolymers were selected as a model
drug targeting system. Copolymers of N-(2-hydroxypropyl)metha-
crylamide (Supplementary Figure 1A) are prototypic and well-
characterised polymeric drug carriers that have been broadly
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simplemented in the delivery of anticancer therapeutics (Kopecek
et al, 2000; Rihova and Kubackova, 2003a; Duncan, 2006; Lammers
et al, 2008). Supplementary Figure 1B schematically depicts the
different copolymers used in this study, functionalised, for
example, with Gd and iodine-131 for imaging purposes, and with
doxorubicin and gemcitabine for therapeutic purposes.
The biodistribution of the copolymers was evaluated by means
of MRI, g-scintigraphy and HPLC. The MR angiography scans in
Figure 2A show that at 0.5h post i.v. injection (p.i.), a 25kDa
gadolinium-labelled HPMA copolymer was localised predomi-
nantly to the vascular compartment. The color-coded maximum
intensity projection (MIP; right panel in Figure 2A) confirms the
long-circulating properties of the copolymer, showing that also in
tumours, the targeting system still resided predominantly within
the vasculature at this time point. Up to 10h p.i., the tumour,
kidney, and liver concentrations (i.e., whole organ levels) of the
conjugate were then compared to those of Gd-DTPA-BMA (i.e.,
gadolinium-diethylenetriaminepentaacetic-acid-bis-methylamide;
Omniscan
s; 0.5kDa), which is a prototypic low molecular weight
MR contrast agent that does not bind to plasma proteins and
that is rapidly eliminated from blood by means of renal filtration.
As shown in Figures 2B and C, it was found that the imple-
mentation of the targeting system attenuated the renal clearance of
the gadolinium label (reducing the initial peak in kidney
accumulation from 60.1±7.5 to 28.5±5.0mM; Po0.05), and that
it consequently – i.e., as a result of the EPR effect (22) – enhanced
its accumulation in tumours over time. Significant localisation
to liver was also noted (Figure 2C), but one needs to take into
account that (I) the weight (and volume) of a rat liver tends to be
B10 times higher than that of an average (10 10mm) AT1
tumour, and that (II) at such ‘early’ time points, the signal
quantified does not necessarily reflect contrast agent accumula-
tion, as significant amounts of the copolymer are still present
in circulation up to 24h (see below), and as the liver is a highly
vascularised organ.
To more extensively evaluate the tumour and organ accumula-
tion of the polymeric drug delivery system, and to do so at later
time points, we next radiolabeled two differently sized tyrosin-
amide-containing HPMA copolymers with iodine-131, and we
monitored their biodistribution scintigraphically. In line with the
MR angiography data Figure 2A, the images in Figure 3A on the
one hand again demonstrate that the polymeric drug carriers
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Figure 2 Magnetic resonance imaging (MRI)-based biodistributional analysis of pHPMA-gadolinium (Gd). (A) MR angiography scans of the chest and head
region of a rat, of a tumour-bearing paw, and of an AT1 tumour, obtained at 0.5h after the intravenous (i.v.) injection of 25kDa pHPMA-Gd. A color-coded
maximal intensity projection (MIP) of the polymer-visualised perfusion of the tumour is depicted in the right panel. (B) Dynamic, color-coded MRI T1
determination obtained for AT1 tumour, for kidney and for liver before contrast agent administration and at various time points after the i.v. injection of a
low (0.5kDa Gd-DTPA-BMA) and high (25kDa Gd-pHPMA) molecular weight MR contrast agent. Note that contrast agent accumulation corresponds to a
decrease in the T1 signal. (C) Quantification of the concentrations of gadolinium in AT1 tumour, kidney, and liver upon the i.v. injection of
Gd-DTPA-BMA and pHPMA-Gd. Values represent average±s.d. (n¼3). * Indicates Po0.05 (paired t-test).
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scirculate for prolonged periods of time, with especially for the
65kDa copolymer, substantial amounts still present in blood at 0.5
and 24h p.i. (as exemplified by the high levels localised to heart).
Quantification of the concentrations of the two copolymers in
systemic circulation confirmed this observation, with at 24h p.i.,
for instance, 11.2±0.7 and 23.7±1.2% of the injected dose still
present in blood for 31 and 65kDa pHPMA, respectively
(Figure 3B). The scintigrams in Figure 3A on the other hand also
quite convincingly demonstrate that the polymeric drug delivery
system presents with an acceptable biodistribution, with besides
localisation to tumours, only indications for an accumulation in
organs of the reticuloendothelial system (RES; i.e., liver, spleen,
and lung), which is known to be involved in the clearance of long-
circulating nanomedicines (Kopecek et al, 2000; Maeda et al, 2000;
Torchilin, 2005; Duncan, 2006). In line with this, when quantifying
the tumour and organ concentrations of the smaller copolymer at
24 and 168h p.i., actually only in spleen, levels were always
significantly higher than in tumours (Figure 3C). In lung, compa-
rable levels were found, and in all other organs, the concentrations
of the copolymer were significantly lower than in tumours. For
65kDa pHPMA, an identical pattern was observed, the only
difference being that the targeting efficacy appeared to be lower at
24h p.i. and higher at 168h p.i. (Figure 3C). This can be explained
by taking the basic principles of EPR and the prolonged circulation
time of the larger copolymer into account (Figure 3B), and is
exemplified by the fact that levels in tumour and spleen
substantially increased and levels in healthy tissues substantially
decreased over time (Figure 3C). The tumour-to-organ ratios in
Figure 3D confirm this observation, showing both higher overall
values and larger increases over time for the 65kDa copolymer,
and they furthermore illustrate that HPMA copolymers localise to
tumours relatively selectively, with throughout follow-up, always
higher levels in tumours than in seven out of nine healthy tissues.
Using HPLC, it was finally demonstrated that by means of their
beneficial biodistributional properties, HPMA copolymers are able
to improve the tumour-directed delivery of doxorubicin, increas-
ing its target site accumulation at 24h p.i. by more than a three-
fold (22.1 vs 6.2mg doxorubicin per gram tumour; Supplementary
Figure 2). Together, these findings show that HPMA copolymers
are able to improve the temporal and spatial parameters of
low molecular weight agents, and they thereby exemplify that
HPMA copolymers are suitable targeting systems for assessing the
validity and the therapeutic potential of carrier-based radio-
chemotherapy.
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Figure 3 HPMA copolymers localise to tumours both effectively and selectively. (A) Scintigraphic analysis of the biodistribution of two differently sized
iodine-131-labelled HPMA copolymers in Copenhagen rats bearing subcutaneously transplanted Dunning AT1 tumours, demonstrating prolonged
circulation and effective tumour accumulation (H: heart (blood), B: bladder, S: spleen, L: liver, T: tumour). (B) Analysis of the blood concentrations of the two
radiolabeled copolymers. Values represent average±s.d. (n¼6). (C) Quantification of the tumour and organ concentrations of the two radiolabeled
copolymers at 24 and 168h post intravenous injection. Values represent average±s.d. (n¼6). Except for lung and spleen, concentrations in tumours were
always significantly higher than those in healthy organs (Po0.05; two-tailed t-test). (D) Quantification of the tumour-to-organ ratios of the copolymers
analysed in (C), pointing out (in green) that they accumulate more selectively in tumours than in seven out of nine healthy tissues.
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sRadiotherapy improves drug targeting
To address the former aspect of carrier-based radiochemotherapy,
that is, to evaluate whether radiotherapy is able to improve the
tumour accumulation of drug targeting systems (Figure 1B), we
next visualised and quantified the concentrations of the iodine-
and gadolinium-labelled copolymers in tumours that were exposed
to 20Gy of radiotherapy 24h before i.v. injection. The scintigrams
in Figure 4A show that as hypothesised, ionising radiation indeed
significantly improved the tumour accumulation of the carrier
systems. Quantifications at 24 and 168h p.i. confirmed this notion,
showing that for the radiolabeled 31kDa copolymer, increases of
24 and 57% were found (Figure 4B), and for the 65kDa copolymer,
increases of 46 and 48%, respectively (Figure 4C). Using the
abovementioned 25kDa gadolinium-containing copolymer and a
1.5T clinical MR scanner, we subsequently also quantified the
tumour accumulation of the targeting system at several earlier time
points, that is, between 0.5 and 24h after i.v. administration. In
this case, upon quantifying the T1 signal enhancements in
irradiated vs control tumours, increases ranging from 31 to 44%
were observed (Figures 4C and D). Even though such increases
may intuitively seem to be modest, in line with previous findings,
using different doses, tumour models, and carrier systems (Li et al,
2000; Davies et al, 2004; Lammers et al, 2007), they do convin-
cingly demonstrate that the tumour accumulation of drug targeting
systems can be improved by combining them with radiotherapy.
This in contrast, for instance, to the majority of targeting ligands
that have been evaluated for this purpose over the years, but that
generally only tend to improve the internalisation of the systems
(Park et al, 2004; Kirpotin et al, 2006).
Drug targeting improves doxorubicin-based
radiochemotherapy
To address the latter (and clinically more relevant) aspect of
carrier-based radiochemotherapy, that is, to investigate whether
drug targeting systems are able to improve the interaction between
radiotherapy and chemotherapy (Figure 1D), two different versions
of HPMA copolymer-bound doxorubicin were synthesised,
that is, poly(HPMA)-GFLG-Dox (PK1; 28 kDa) and human
immunoglobulin G-modified poly(HPMA)-GFLG-Dox (IgG-PK1;
900 kDa). Both polymeric prodrugs have been tested in clinical
trials, and both have been shown to be at least equally effective as
free doxorubicin (Kopecek et al, 2000; Bilim, 2003; Rihova and
Kubackova, 2003a; Rihova et al, 2003b; Duncan, 2006). As the MTD
of PK1 is known to be 4–5 times higher than that of free
doxorubicin (both in humans and in rodents (Yeung et al, 1991;
Vasey et al, 1999)), in an attempt to simultaneously increase the
efficacy and reduce the toxicity of the intervention, we chose to
apply PK1 at three times 5mgkg
 1 (days 1, 8, and 15), that is, at
twice the dose used for free doxorubicin, which has a cumulative
MTD of 7.5mgkg
 1 in rats. IgG-PK1 was applied both at the 2.5 and
at the 5mg
 1kg regimen. As shown in Figure 5A, in the aggressively
growing and radio- and chemoresistant Dunning AT1 model, all
three doxorubicin formulations were found to be significantly more
effective than control, but the improvements were rather modest,
and neither PK1 nor IgG-PK1 turned out to be better than the free
drug. When combined with 20 daily doses of 2Gy of local tumour
radiotherapy, however, in line with our rationale (Figure 1), the two
polymeric prodrugs did present with a significantly higher
therapeutic index than did the free drug: PK1 applied at three
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Figure 4 Radiotherapy (RT) improves drug targeting. (A) Scintigraphic analysis of the effect of 20Gy of local tumour RT on the tumour accumulation of
an iodine-131-labelled 31kDa HPMA copolymer, demonstrating that RT beneficially affects tumour targeting. (B) Quantification of the effect of RT on the
tumour concentrations of the 31kDa (left panel) and 65kDa (right panel) copolymer at 24 and 168h post intravenous injection. Values represent
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s5mgkg
 1 doses and IgG-PK1 applied at three 2.5mgkg
 1 doses
were both found to be substantially more effective than three
2.5mgkg
 1 doses of free doxorubicin (Figures 5B and C), and both
were also significantly less toxic (Figure 5D). For the former two
regimens, a dose-enhancement factor (DEF; i.e., a routinely used
parameter for assessing the radiosensitising potential of chemother-
apeutic agents) of 1.50 was found, as compared to a DEF of only 1.28
for the free drug (Supplementary Table 1). With a DEF of 1.82, IgG-
PK1 applied at three 5mgkg
 1 doses was found to be by far the
most effective regimen for improving the efficacy of fractionated
radiotherapy (Figures 5B and C). It was, however, also the most
toxic treatment (Figure 5D), which underlines the importance of
determining an optimal dosing regimen for each individual agent.
As it was found that both for PK1 (3 5mgkg
 1)a n df o rI g G - P K 1
(3 2.5mgkg
 1), the efficacy of the intervention was increased
while its toxicity was reduced, these findings were considered to be
an initial indication for the fact that drug targeting systems are able
to improve the therapeutic index of radiochemotherapy.
Preparation of gemcitabine-containing HPMA copolymers
To provide additional evidence for the validity of carrier-based radio-
chemotherapy, we subsequently synthesised pHPMA-Gemcitabine.
Gemcitabine is a well-known radiosensitiser (Lawrence et al,
1997), and it is used in the first-line treatment of various advanced
solid malignancies. Two different gemcitabine-containing copoly-
mers were prepared, termed A-Gem and B-Gem (Figures 6A and
B). In A-Gem, the drug is conjugated to the copolymer by means
of the uncleavable aminohexanoic acid spacer. In B-Gem,
gemcitabine is attached to the polymeric backbone by means of
the -GFLG- spacer, which is also used in PK1 and which is known
to be cleaved by the lysosomal cysteine protease cathepsin B.
Figure 6C shows that A-Gem does not release the drug in vitro:
independent of the conditions used, less than 1% of the agent
was liberated upon 8h of incubation. B-Gem, on the other hand,
was quite effective in releasing gemcitabine: at pH¼6, B10%
was released after 8h, at pH¼7.4, B30% was released, and
upon incubation with physiologically relevant concentrations of
cathepsin B (at pH¼6; resembling endo- and lysosomal condi-
tions), the total amount of drug conjugated to the copolymer was
released within less than 6h (Figure 6D). To demonstrate that the
extent of drug release correlates with the cytotoxicity of the
conjugates, clonogenic survival assays were performed. As shown
in Figures 6E and F, as expected, both in Dunning AT1 rat prostate
carcinoma cells and in A2780 human ovarian carcinoma cells,
B-Gem was significantly more effective than A-Gem. In addi-
tion, also in line with our expectations, the two carrier-based
agents were found to be less effective in vitro than the free
Control A
Dox: 3×2.5 mg kg–1
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Figure 5 Drug targeting improves doxorubicin (Dox)-based radiochemotherapy. (A) Growth inhibition of Dunning AT1 tumours induced by three
intravenous (i.v.) injections (days 1, 8, and 15; see vertical arrows) of saline, of free doxorubicin and HPMA copolymer-bound doxorubicin. PK1: pHPMA-
GFLG-Dox (28kDa). IgG-PK1: human IgG-modified pHPMA-GFLG-Dox (900kDa). Values represent average ± s.e.m (n¼6–12). *Indicates Po0.05 vs
control (Mann–Whitney U-test; Bonferroni–Holm post hoc analysis). (B) Tumour growth inhibition induced by three i.v. injections of the abovementioned
chemotherapeutic agents in combination with a clinically relevant regimen of fractionated radiotherapy (20 2Gy; see vertical lines). Values represent
average±s.e.m. (n¼8–10). * Indicates Po0.05 vs control,
# indicates Po0.05 vs free Dox, and
w indicates Po0.005 vs free Dox (Mann–Whitney U-test;
Bonferroni–Holm post hoc analysis). (C) Representative images (day 50) of tumours treated with the indicated combination regimens. (D) Weight loss
induced by doxorubicin-based combined modality therapy. Values represent average±s.e.m. (n¼4–5).
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sagent. For a drug-free control copolymer, no cytotoxicity was
observed.
Drug targeting improves gemcitabine-based
radiochemotherapy
In the final set of experiments, we set out to investigate the in vivo
potential of HPMA copolymer-bound gemcitabine. As shown in
Figure 7A, it was again found that without radiotherapy, neither
the free drug nor its polymeric prodrugs were able to induce
substantial growth inhibition in the therapy-resistant Dunning
AT1 model: B-Gem applied at four 3mgkg
 1 doses appeared to be
the only regimen that was significantly more effective than control,
but it was not more effective than free gemcitabine (Supplemen-
tary Table 2). In line with our rationale (Figure 1), however, upon
again combining the agents with a clinically relevant regimen of
fractionated radiotherapy (12 3Gy), it could again be observed
that the targeted formulation was significantly more effective than
the free drug (Figures 7B and C): for B-Gem, a DEF of 2.79 was
found, as compared to a DEF of ‘only’ 2.14 for free gemcitabine
(Supplementary Table 2). Figure 7D and Supplementary Figure 3
finally show that the combination of B-Gem with fractionated
radiotherapy was equally well tolerated as the combination of free
gemcitabine with fractionated RT, with both agents inducing an
identical degree of weight loss and of bone marrow suppression. In
line with the results obtained for doxorubicin (Figure 5), these
notions exemplify that drug targeting systems are able to increase
the efficacy of radiochemotherapy without increasing its toxicity.
DISCUSSION
Over the years, a variety of different drug targeting systems have
been developed, ranging in nature from simple polymers (Duncan,
2006) and liposomes (Torchilin, 2005), to stimuli-sensitive
polymeric micelles (Rapoport et al, 2007), bacterially derived
Minicells (MacDiarmid et al, 2007), and temporally targeted
Nanocells (Sengupta et al, 2005). Thus far, however, not very many
have managed to reach the final stages of clinical evaluation, and
only about a handful have been approved by the responsible
regulatory authorities. Consequently, hardly any information is
available on the combination of tumour-targeted nanomedicines
with other well-established treatment modalities. The potential of
combining them with a clinically relevant regimen of fractionated
radiotherapy, for instance, has not yet been properly evaluated,
even though there is an obvious rationale for doing so (Figure 1).
We have here used the prototypic polymeric drug carrier
pHPMA to validate the potential of this targeted combination
regimen. In line with the literature (Kopecek et al, 2000), HPMA
copolymers were hereto first shown to be versatile and multi-
functional drug carriers, that can be easily tracked in vivo, that
circulate for prolonged periods of time, that localise to tumours
both effectively and selectively, and that improve the tumour-
targeted delivery of low molecular weight agents (Figures 2 and 3).
Subsequently, they were then shown to interact synergistically with
radiotherapy, with radiotherapy increasing the tumour accumula-
tion of the copolymers (Figure 4), and with the copolymers
increasing the therapeutic index of radiochemotherapy (Figures 5
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Figure 6 Characterisation of the gemcitabine (Gem)-containing HPMA copolymers. (A) and (B) Chemical structure of A-Gem (poly(HPMA)-AH-Gem)
and B-Gem (poly(HPMA)-GFLG-Gem). (C and D) Release of gemcitabine from A-Gem and B-Gem at pH¼7.4, at pH¼6.0, and at pH¼6.0 in the
presence of the lysosomal cysteine protease cathepsin B (CB). Values are expressed relative to the total amount of drug conjugated to the copolymers, and
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copolymer. Colony formation assays were performed using Dunning AT1 rat prostate carcinoma cells (E) and A2780 human ovarian carcinoma cells (F).
Values represent average±s.d. (n¼3).
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sand 7). Improvements were observed in a rapidly growing and
therapy-resistant tumour model, and both for doxorubicin and for
gemcitabine, together indicating that ‘carrier-based radiochemo-
therapy’ is indeed a promising approach for improving the efficacy
of combined modality anticancer therapy.
This notion is in line with the results of a recently published
phase I trial, in which 12 patients with localised oesophageal and
gastric cancer were treated with the combination of poly(L-
glutamic acid) (PGA)-bound paclitaxel (Xyotax; 6 doses; weekly)
and fractionated radiotherapy (28 cycles; 1.8Gy; daily), and in
which four complete responses and an additional seven partial
responses (with reductions in tumour size of more than 50%) were
achieved (Dipetrillo et al, 2006). Prior to this trial, preclinical
studies had already identified Xyotax as a highly potent radio-
sensitiser. When a single i.v. injection of Xyotax was combined
with a single dose of radiotherapy, for instance, the dose required
to produce 50% tumour cure (TCD50) could be reduced substan-
tially, from 53.9 to 7.5Gy (Milas et al, 2003). When radiotherapy
was delivered as five daily fractions, the effect of Xyotax was even
more pronounced reducing the TCD50 from 66.6 to 7.9Gy. In a
follow-up study in the same tumour model (i.e., C3Hf/KamLaw
mice bearing B7mm syngeneic OCa-1 ovarian adenocarcinomas),
similar results were reported for Abraxane, that is, for albumin-
based paclitaxel, which also beneficially combined both with single
dose and with fractionated radiotherapy, and which did not
increase normal tissue radiotoxicity (Wiedenmann et al, 2007).
In comparable analyses, Harrington et al (2000) have
demonstrated that also liposomes hold significant potential for
combination with radiotherapy. They combined both PEGylated
liposomal doxorubicin and PEGylated liposomal cisplatin with
both single dose (4.5 and 9Gy) and fractionated (3 3Gy)
radiotherapy, and they showed that animals treated with carrier-
based radiochemotherapy survived for significantly longer periods
of time than did animals treated with standard radiochemo-
therapy. Davies et al (2004) recently confirmed and extended
these findings, showing that PEGylated liposomal doxorubicin
(Caelyx; Doxil) significantly improves the efficacy of both single-
dose (8Gy) and fractionated (3 3.6Gy) radiotherapy, and that
it does so, at least in part, by improving the penetration and
the intratumoral distribution of the agent. In their studies on
polymeric radiosensitisers, Li et al (2000) also observed that
radiotherapy increases the tumour accumulation of passively
targeted nanomedicines, attributing at least part of the supra-
additively improved efficacy of PGA-paclitaxel (Xyotax) and
radiotherapy to a radiotherapy-induced increase in tumour
localisation. It is interesting to note in this regard that the overall
improvement in the tumour concentration of PGA-paclitaxel was
virtually identical to that observed here for HPMA copolymers,
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Figure 7 Drug targeting improves gemcitabine (Gem)-based radiochemotherapy. (A) Growth inhibition of Dunning AT1 tumours induced by four
intravenous (i.v.) injections (days 1, 8, 15, and 22; see vertical arrows) of saline, free gemcitabine and HPMA copolymer-bound gemcitabine. A-Gem:
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# indicates Po0.0005 vs control, and
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images (day 45) of tumours treated with the indicated combination regimens. (D) Weight loss induced by gemcitabine-based combined modality therapy.
Values represent average±s.e.m. (n¼5–6).
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swith as compared to sham-irradiated controls, increases ranging
from 25 to 50%. Also in line with our findings, Li et al
demonstrated that this radiotherapy-induced increase in tumour
accumulation could already be observed almost immediately upon
i.v. injection (i.e., at 1h p.i. vs at 30min p.i. here), and remains
relatively constant over time. Together with Davies et al’s findings
on the enhanced penetration and the improved intratumoral
distribution of PEGylated liposomal doxorubicin in response to
radiotherapy, these observations suggest that radiotherapy bene-
ficially affects both arms of the EPR effect: on the one hand, by
e.g. enhancing the expression of VEGF (Li et al, 2000; Park et al,
2001), it likely increases the permeability of the tumour blood
vessels towards long-circulating nanomedicines, and on the other
hand, by e.g. reducing the tumour cell density (Peschke et al, 1999)
and the interstitial fluid pressure (Znati et al, 1996), it likely
enhances their retention and their intratumoral distribution.
Although clinically clearly less important than the improved
therapeutic indices resulting from carrier-based radiochemo-
therapy, these improvements in EPR-mediated drug targeting to
tumours provide an additional rationale for combining tumour-
targeted nanomedicines with radiotherapy.
In summary, using prototypic polymeric drug carriers, two
different imaging techniques and two different chemotherapeutic
agents, we here demonstrate that drug targeting and radiotherapy
interact synergistically, with radiotherapy increasing the tumour
accumulation of drug targeting systems, and with drug targeting
systems increasing the therapeutic index of radiochemotherapy.
We extend previous efforts by attempting to generalise the concept
of ‘carrier-based radiochemotherapy’, by implementing clinically
relevant regimens of radio- and chemotherapy, and by directly
comparing the radiosensitising potential of polymeric prodrugs to
that of free chemotherapeutic agents. The results presented and the
insights obtained strongly suggest that carrier-based radiochemo-
therapy holds significant potential for improving the treatment of
advanced solid malignancies.
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